Registration - In-house Corporation

Hoffmann-La Roche Limited / BRIGITTE NOLET, PRESIDENT AND CHIEF EXECUTIVE OFFICER

Registration Information

In-house Corporation name: Hoffmann-La Roche Limited
Previous in-house corporation names
Responsible Officer Name: BRIGITTE NOLET, PRESIDENT AND CHIEF EXECUTIVE OFFICER
Responsible Officer Change History
Initial registration start date: 2001-01-18
Registration status: Active
Registration Number: 952745-64

Associated Communications

Total Number of Communication Reports: 479

Monthly communication reports in the last 6 months: 8

Version 52 of 67 (2021-12-13 to 2022-01-19)

Registration versions:

Version 52 of 67 (2021-12-13 to 2022-01-19)

Lobbying Information

Subject Matters

Economic Development
Employment and Training
Health
Industry
Intellectual Property
Internal Trade
Research and Development
Science and Technology

Subject Matter Details

Grant, Contribution or Other Financial Benefit

Strategic Innovation Fund, as it relates to any initiative submitted or supported.

Legislative Proposal, Bill or Resolution

Comprehensive Economic Trade Agreement with Europe (CETA) and pharmaceutical intellectual property protection
Food and Drugs Act Modernization initiative as it relates to reform of drug submission review and approval process
Food and Drugs Act and Regulations, as they relate to drug export and cross-border trade
Food and Drugs Act and Regulations, as they relate to the establishment of an approval framework for subsequent entry biologic products
Food and Drugs Act and Regulations, as they relate to the provision of data exclusivity for innovative drug products
Food and Drugs Act and Regulations, as they relate to the review and approval of new drug submissions and post market surveillance of drug products
House of Commons Standing Committee of Health's (HESA) as it relates to Pharmacare, rare disease and/or any other pertinent legislative proposal before the committee
Patent Act and Patented Medicines (Notice of Compliance) Regulations, as it relates to the regulation of intellectual property, approval for therapeutic products, changes to modernize the Right of Appeal
Patent Act as it relates to changes affecting term restoration or Canada's Access to Medicines Regime
Patented Medicines Prices Review Board (PMPRB), as it relates to reporting requirements, pricing guidelines, and dispute resolution
United States, Mexico, Canada Agreement (USMCA) and pharmaceutical intellectual property protection.

Policies or Program

Biologics and Genetic Therapies Directorate as it relates to policies affecting the review and approval of submissions
Clinical Trials environment in Canada: operational issues, investment, enrollment
Economic Growth Initiatives as it relates to pharmaceutical, clinical trials investment, life sciences industry
Innovation Agenda - as it relates to the Life Science Industry and the Federal Initiative lead by Innovation, Science, Economic Development
National Pharmaceutical Strategy and negotiation of the Health Accord, as it relates to National Pharmacare/universal or catastrophic drug coverage, Drug policies & Pricing.
Pandemic Planning as it relates to the Task Group on Antiviral Prophylaxis recommendations
Policies related to Subsequent Entry Biologics (SEBs) pertaining to Draft Guidance for Sponsors; Information and Submission requirements for SEBs, regulations and intellectual property policies, naming conventions
Policies related to rare disease as it relates to separate regulatory pathway for drugs for rare diseases and government strategies.
Policies related to the importation of pharmaceuticals from Canada to the United States

Policies or Program, Regulation

Orphan Drug Regulatory Framework as it relates to separate regulatory pathway for drugs for rare diseases

Regulation

Health Canada/PMPRB proposed regulation changes to the Patented Medicines Regulations.

Communication Techniques

Written communication
Oral communication

Government Institutions

Canadian Institutes of Health Research (CIHR)
Environment and Climate Change Canada (ECCC)
Federal Economic Development Agency for Southern Ontario (FedDev)
Finance Canada (FIN)
Global Affairs Canada (GAC)
Health Canada (HC)
House of Commons
Innovation, Science and Economic Development Canada (ISED)
National Research Council (NRC)
Patented Medicine Prices Review Board (PMPRB)
Prime Minister's Office (PMO)
Privy Council Office (PCO)
Public Health Agency of Canada (PHAC)
Public Services and Procurement Canada (PSPC)
Senate of Canada
Treasury Board Of Canada Secretariat (TBS)

In-house Corporation Details

Description of activities

Hoffmann-La Roche Limited deals with the healthcare system in the prevention, screening, diagnosis, treatment and management of acute and long-term disease and supports leading research and development - including clinical research, clinical trials and genetic research.

Responsible officer name and position during the period of this registration

RONNIE MILLER, PRESIDENT AND CHIEF EXECUTIVE OFFICER

Government funding

No government funding was received during the last completed financial year.

In-house Corporation Contact Information

Address:
7070 Mississauga Road
Mississauga, ON L5N 5M8
Canada

Telephone number: 905-542-5555

Parent Company Information

F. Hoffmann-La Roche AG
- Grenzacherstrasse 124
  4070 Basle
  Switzerland

Subsidiary Beneficiary Information

Hoffmann-La Roche Limited does not have any subsidiaries that could have a direct interest in the outcome of the undertaking

Lobbyists Details

Senior Officers whose lobbying activities represent less than 20% of their Duties

Matthew Bureau, Healthcare Systems Partner | No public offices held
Michele D'Elia, Executive Director, Medical & Scientific Affairs | No public offices held
Andrew Plank, President & General Manager, Roche Diagnostics | No public offices held
Dvorah Richler, Strategic Healthcare Partner | No public offices held
Roger Tam, Vice President, Legal | No public offices held
Carlene Todd, Vice President, Access | No public offices held
Bill Zindle, Executive Director, Strategy and Marketing | No public offices held

Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties

Logan Caragata, Head, Healthcare System Strategy & Government Affairs | No public offices held
Francois Drolet, Executive Director, Access, Policy & Government Relations | No public offices held
Cassondra McCrory, Healthcare System Partner, Federal | No public offices held

Hoffmann-La Roche Limited

The following names have been used on or after July 2, 2008

Name	From	To
Hoffmann-La Roche Limited	2008-08-13	current

The following names have been used before July 2, 2008

Hoffmann-La Roche Limited
HOFFMANN-LA ROCHE LIMITED

Hoffmann-La Roche Limited

Responsible Officer History
Responsible Officer Name	From (YYYY-MM-DD)	To (YYYY-MM-DD)
BRIGITTE NOLET	2022-08-01	Current
RONNIE MILLER	2001-01-18	2022-08-01

Date Modified:: 2025-04-30

Search and menus

Language selection

Registration - In-house Corporation

Hoffmann-La Roche Limited / BRIGITTE NOLET, PRESIDENT AND CHIEF EXECUTIVE OFFICER

Registration Information

Associated Communications

Version 52 of 67 (2021-12-13 to 2022-01-19)

Version 52 of 67 (2021-12-13 to 2022-01-19)

Subject Matters

Subject Matter Details

Grant, Contribution or Other Financial Benefit

Legislative Proposal, Bill or Resolution

Policies or Program

Policies or Program, Regulation

Regulation

Communication Techniques

Government Institutions

Description of activities

Responsible officer name and position during the period of this registration

Government funding

In-house Corporation Contact Information

Parent Company Information

Subsidiary Beneficiary Information

Senior Officers whose lobbying activities represent less than 20% of their Duties

Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties